U.S. markets closed
  • S&P 500

    4,352.63
    -90.48 (-2.04%)
     
  • Dow 30

    34,299.99
    -569.38 (-1.63%)
     
  • Nasdaq

    14,546.68
    -423.29 (-2.83%)
     
  • Russell 2000

    2,229.78
    -51.23 (-2.25%)
     
  • Crude Oil

    74.33
    -1.12 (-1.48%)
     
  • Gold

    1,733.90
    -18.10 (-1.03%)
     
  • Silver

    22.47
    -0.23 (-1.01%)
     
  • EUR/USD

    1.1685
    -0.0016 (-0.14%)
     
  • 10-Yr Bond

    1.5340
    +0.0500 (+3.37%)
     
  • GBP/USD

    1.3536
    -0.0168 (-1.23%)
     
  • USD/JPY

    111.4820
    +0.5040 (+0.45%)
     
  • BTC-USD

    41,992.65
    -875.17 (-2.04%)
     
  • CMC Crypto 200

    1,033.22
    -23.93 (-2.26%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

Here's What Molecular Templates, Inc.'s (NASDAQ:MTEM) Shareholder Ownership Structure Looks Like

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Molecular Templates, Inc. (NASDAQ:MTEM) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned.

Molecular Templates is not a large company by global standards. It has a market capitalization of US$381m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Molecular Templates.

Check out our latest analysis for Molecular Templates

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Molecular Templates?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Molecular Templates. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Molecular Templates, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 5.1% of Molecular Templates shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that Bellevue Asset Management AG is the largest shareholder with 17% of shares outstanding. With 13% and 5.7% of the shares outstanding respectively, Santé Ventures, LLC and Longitude Capital Management Co., LLC are the second and third largest shareholders.

We did some more digging and found that 6 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Molecular Templates

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our information suggests that Molecular Templates, Inc. insiders own under 1% of the company. It has a market capitalization of just US$381m, and the board has only US$2.5m worth of shares in their own names. Many tend to prefer to see a board with bigger shareholdings. A good next step might be to take a look at this free summary of insider buying and selling.

General Public Ownership

The general public holds a 10% stake in Molecular Templates. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 18%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Public Company Ownership

Public companies currently own 5.2% of Molecular Templates stock. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Molecular Templates better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Molecular Templates you should be aware of, and 1 of them makes us a bit uncomfortable.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.